Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess
the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous
Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or
uncontrolled hypertension
Phase
Phase 3
Funding Agency/Sponsor
Industry
Disease
Other
Enrollment Eligibility
Inclusion Criteria:
- Has a confirmed diagnosis of endogenous Cushing syndrome
- Meets at least one of the following criteria:
- Has Type 2 diabetes mellitus
- Has impaired glucose tolerance
- Has hypertension
Exclusion Criteria:
- Has non-endogenous source of hypercortisolemia
- Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
- Has poorly controlled hypertension
- Has poorly controlled diabetes mellitus
- Has severe renal insufficiency